APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hormone Refractory Prostate Cancer (HRPCA)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast 2026-2032

21 December 2025195 pages

Choose your research edition.

Industry ResearchHormone Refractory Prostate Cancer (HRPCA) Industry Research Report 2026104 pages · $2,950 USDIndustry Growth & TrendsGlobal Hormone Refractory Prostate Cancer (HRPCA) Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal Hormone Refractory Prostate Cancer (HRPCA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hormone Refractory Prostate Cancer (HRPCA) Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Hormone Refractory Prostate Cancer (HRPCA) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hormone Refractory Prostate Cancer (HRPCA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hormone Refractory Prostate Cancer (HRPCA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hormone Refractory Prostate Cancer (HRPCA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hormone Refractory Prostate Cancer (HRPCA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hormone Refractory Prostate Cancer (HRPCA) include Sanofi S.A, Johnson & Johnson, Astellas Inc and Dendreon Corporation, Bayer AG, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hormone Refractory Prostate Cancer (HRPCA), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hormone Refractory Prostate Cancer (HRPCA), also provides the revenue of main regions and countries. Of the upcoming market potential for Hormone Refractory Prostate Cancer (HRPCA), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hormone Refractory Prostate Cancer (HRPCA) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hormone Refractory Prostate Cancer (HRPCA) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hormone Refractory Prostate Cancer (HRPCA) revenue, projected growth trends, production technology, application and end-user industry.

Hormone Refractory Prostate Cancer (HRPCA) Segment by Company

Sanofi S.A

Johnson & Johnson

Astellas Inc

Dendreon Corporation, Bayer AG

Hormone Refractory Prostate Cancer (HRPCA) Segment by Type

Vaccines

Cytotoxic Agents

Anti-Androgens

Radio-Pharmaceuticals

Hormone Refractory Prostate Cancer (HRPCA) Segment by Application

Specialty Clinics

Hospitals

Ambulatory Surgical Centers

Others

Hormone Refractory Prostate Cancer (HRPCA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hormone Refractory Prostate Cancer (HRPCA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hormone Refractory Prostate Cancer (HRPCA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hormone Refractory Prostate Cancer (HRPCA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hormone Refractory Prostate Cancer (HRPCA) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hormone Refractory Prostate Cancer (HRPCA) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vaccines Major Player Table 3. Cytotoxic Agents Major Player Table 4. Anti-Androgens Major Player Table 5. Radio-Pharmaceuticals Major Player Table 6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Specialty Clinics Major Player Table 8. Hospitals Major Player Table 9. Ambulatory Surgical Centers Major Player Table 10. Others Major Player Table 11. Hormone Refractory Prostate Cancer (HRPCA) Industry Trends Table 12. Hormone Refractory Prostate Cancer (HRPCA) Industry Drivers Table 13. Hormone Refractory Prostate Cancer (HRPCA) Industry Opportunities and Challenges Table 14. Hormone Refractory Prostate Cancer (HRPCA) Industry Restraints Table 15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2021-2026) Table 18. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2027-2032) Table 20. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2021-2026) Table 22. Global Hormone Refractory Prostate Cancer (HRPCA) Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Hormone Refractory Prostate Cancer (HRPCA) Key Players Headquarters & Area Served Table 24. Global Hormone Refractory Prostate Cancer (HRPCA) Players, Product Type & Application Table 25. Global Hormone Refractory Prostate Cancer (HRPCA) Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Hormone Refractory Prostate Cancer (HRPCA) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2021-2026) Table 32. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2027-2032) Table 33. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2021-2026) Table 37. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2027-2032) Table 38. Sanofi S.A Company Information Table 39. Sanofi S.A Business Overview Table 40. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 42. Sanofi S.A Recent Development Table 43. Johnson & Johnson Company Information Table 44. Johnson & Johnson Business Overview Table 45. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 47. Johnson & Johnson Recent Development Table 48. Astellas Inc Company Information Table 49. Astellas Inc Business Overview Table 50. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 52. Astellas Inc Recent Development Table 53. Dendreon Corporation, Bayer AG Company Information Table 54. Dendreon Corporation, Bayer AG Business Overview Table 55. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 57. Dendreon Corporation, Bayer AG Recent Development Table 58. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (US$ Million) Table 59. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032) & (US$ Million) Table 60. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (US$ Million) Table 61. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032) & (US$ Million) Table 62. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 63. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026) & (US$ Million) Table 64. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (US$ Million) & (2027-2032) Table 65. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (US$ Million) Table 66. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032) & (US$ Million) Table 67. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (US$ Million) Table 68. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032) & (US$ Million) Table 69. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026) & (US$ Million) Table 71. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (US$ Million) & (2027-2032) Table 72. China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (US$ Million) Table 73. China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032) & (US$ Million) Table 74. China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (US$ Million) Table 75. China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032) & (US$ Million) Table 76. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (US$ Million) Table 77. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032) & (US$ Million) Table 78. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (US$ Million) Table 79. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032) & (US$ Million) Table 80. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 81. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Region (US$ Million) & (2021-2026) Table 82. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Region (US$ Million) & (2027-2032) Table 83. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (US$ Million) Table 84. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032) & (US$ Million) Table 85. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (US$ Million) Table 86. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032) & (US$ Million) Table 87. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026) & (US$ Million) Table 89. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (US$ Million) & (2027-2032) Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Hormone Refractory Prostate Cancer (HRPCA) Image Figure 2. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vaccines Image Figure 5. Cytotoxic Agents Image Figure 6. Anti-Androgens Image Figure 7. Radio-Pharmaceuticals Image Figure 8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share 2021 VS 2025 VS 2032 Figure 10. Specialty Clinics Image Figure 11. Hospitals Image Figure 12. Ambulatory Surgical Centers Image Figure 13. Others Image Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million) & (2021-2032) Figure 15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Hormone Refractory Prostate Cancer (HRPCA) Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2021-2032) Figure 22. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2021-2032) Figure 25. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032) Figure 27. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032) Figure 28. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Country (2021-2032) Figure 29. United States Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032) Figure 34. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032) Figure 35. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Country (2021-2032) Figure 36. Germany Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032) Figure 46. China Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032) Figure 47. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032) Figure 49. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032) Figure 50. Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Region (2021-2032) Figure 51. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032) Figure 59. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032) Figure 60. SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Country (2021-2032) Figure 61. Brazil Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Hormone Refractory Prostate Cancer (HRPCA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccines
  • Cytotoxic Agents
  • Anti-Androgens
  • Radio-Pharmaceuticals
Applications
  • Specialty Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Sanofi S.A
  • Johnson & Johnson
  • Astellas Inc
  • Dendreon Corporation, Bayer AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hormone Refractory Prostate Cancer (HRPCA) Market by Type
  3. 1.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vaccines
  5. 1.2.3 Cytotoxic Agents
  6. 1.2.4 Anti-Androgens
  7. 1.2.5 Radio-Pharmaceuticals
  8. 1.3 Hormone Refractory Prostate Cancer (HRPCA) Market by Application
  9. 1.3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Specialty Clinics
  11. 1.3.3 Hospitals
  12. 1.3.4 Ambulatory Surgical Centers
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics
  1. 2.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends
  2. 2.2 Hormone Refractory Prostate Cancer (HRPCA) Industry Drivers
  3. 2.3 Hormone Refractory Prostate Cancer (HRPCA) Industry Opportunities and Challenges
  4. 2.4 Hormone Refractory Prostate Cancer (HRPCA) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Perspective (2021-2032)
  2. 3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Growth Trends by Region
  3. 3.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2021-2026)
  5. 3.2.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players
  2. 4.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players (2021-2026)
  3. 4.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hormone Refractory Prostate Cancer (HRPCA) Key Players Headquarters & Area Served
  7. 4.4 Global Hormone Refractory Prostate Cancer (HRPCA) Players, Product Type & Application
  8. 4.5 Global Hormone Refractory Prostate Cancer (HRPCA) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market CR5 and HHI
  11. 4.6.3 2025 Hormone Refractory Prostate Cancer (HRPCA) Tier 1, Tier 2, and Tier 3
5 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
  1. 5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2032)
  3. 5.3 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2021-2032)
6 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
  1. 6.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2032)
  3. 6.3 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi S.A
  2. 7.1.1 Sanofi S.A Company Information
  3. 7.1.2 Sanofi S.A Business Overview
  4. 7.1.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  6. 7.1.5 Sanofi S.A Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Astellas Inc
  14. 7.3.1 Astellas Inc Company Information
  15. 7.3.2 Astellas Inc Business Overview
  16. 7.3.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  18. 7.3.5 Astellas Inc Recent Developments
  19. 7.4 Dendreon Corporation, Bayer AG
  20. 7.4.1 Dendreon Corporation, Bayer AG Company Information
  21. 7.4.2 Dendreon Corporation, Bayer AG Business Overview
  22. 7.4.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  24. 7.4.5 Dendreon Corporation, Bayer AG Recent Developments
8 North America
  1. 8.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue (2021-2032)
  2. 8.2 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2032)
  3. 8.2.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026)
  4. 8.2.2 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032)
  5. 8.3 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032)
  6. 8.4 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2032)
  7. 8.4.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026)
  8. 8.4.2 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032)
  9. 8.5 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032)
  10. 8.6 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country
  11. 8.6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026)
  13. 8.6.3 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue (2021-2032)
  2. 9.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032)
  5. 9.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032)
  9. 9.5 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country
  11. 9.6.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hormone Refractory Prostate Cancer (HRPCA) Revenue (2021-2032)
  2. 10.2 China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2032)
  3. 10.2.1 China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026)
  4. 10.2.2 China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032)
  5. 10.3 China Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032)
  6. 10.4 China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2032)
  7. 10.4.1 China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026)
  8. 10.4.2 China Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032)
  9. 10.5 China Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue (2021-2032)
  2. 11.2 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032)
  5. 11.3 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032)
  9. 11.5 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country
  11. 11.6.1 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue (2021-2032)
  2. 12.2 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country
  11. 12.6.1 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst